Daily treatment with SMT C1100 dramatically reduces muscular dystrophy symptoms in mdx mouse - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

Daily treatment with SMT C1100 dramatically reduces muscular dystrophy symptoms in mdx mouse - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "Summit plc based in Abingdon, UK, together with the Davies group (University of Oxford) and collaborators have reported exciting results from its latest studies of its utrophin upregulator drug SMT C1100. It has developed a small molecule based drug that can be taken orally once a day which could treat all patients with muscular dystrophy regardless of their specific gene defect. The studies took place using the mdx mouse, a recognised model for Duchenne Muscular Dystrophy study and in human tissues in the lab. The results showed increased utrophin in muscles and that this helped increase the amount of exercise achievable and therefore overall strength. These significant results demonstrate the potential importance of SMT C1100 and should pave the way for the next human trials of the drug."